Pfizer has confirmed a temporary suspension of its Premarin brand of vaginal cream in India. The update means the product is currently unavailable in the market while the company addresses the issue.
According to Pfizer, the interruption is linked to supply constraints. The company said it is evaluating options to restore availability, but it has not indicated when supplies may return to normal.
The confirmation provides clarity on the status of the medicine in India and highlights how supply disruptions can affect access to branded treatments. In such situations, healthcare providers and patients often have to monitor availability closely while waiting for stock to resume.
Pfizer's statement suggests the move is temporary rather than a permanent withdrawal of the product from India. For now, the focus remains on resolving the supply problem and bringing Premarin vaginal cream back to the market.
